KALY – Kali-Extracts, Inc. Previews Pending Report On Cannabis Treatment For Lung Disease Study

DALLAS, Feb. 21, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today published a second preview of a pending full report on their long-term, pilot study on the treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates with cannabis extracts derived from Kali-Extracts patented cannabis extraction process.  The first preview was published on February 5, 2019.  The full report is expected within the next 2 weeks. The primate study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients.  The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.

The primate study was conducted by Professor Jeffry Osbourn, Ph.D., from the University of Kentucky and his Biomedical Science Research Group (BSRG).  Professor Osbourn made the following statement in regard to the research adding to his original statement published on February 5^th, 2019:

“We investigated the effects of a novel, new agent for the oral treatment of lung diseases like inflammation of the lung airways in nonhuman primates with chronic pulmonary fibrosis. The new NCM Biotech supplement was evaluated at 3 separate concentrations and compared to placebo treated animals. After only 2 weeks of daily oral treatment, a 5 fold dilution of the supplement extract increased respiration rate by 55%, airway flow rate by 82%, inspiratory airway flow velocity by 149%, and tidal volume by 38% compared to each animal’s own control values. Blood pressure and heart rate were not changed by the compound during this time frame. These large increases in pulmonary function in fibrotic lungs elicited marked increases in resting minute ventilation in these animals. A full report of the detailed data will be available within the next 2 weeks. Larger dilution (25 fold) had little to no effect on airway or lung functions. Further evaluation of this oral supplement is planned for determining the histological and gene regulatory changes in pulmonary airways, short and long term pharmacological compound distribution and renal/hepatic handling of the extract as well as molecular gas chromatography, mass spectroscopy assessment of the biologically active components. These future experiments are designed to more closely identify the mechanisms of this improved overall lung function leading to greatly improved life styles and activity levels for the large numbers of patients suffering from chronic pulmonary fibrosis.”

Kali-Extracts, Inc. (“KALY”) is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies.  KALY is utilizing its patented cannabis extraction process to develop numerous wellness products both internally and through partnerships. Similarly, KALY is utilizing its patented cannabis extraction technology to develop pharmaceutical products internally and through partnerships.

KALY has licensed its extraction process to Puration, Inc. (PURA) (“PURA”) for the production of beverages.  With over $1 million in trailing twelve-month sales, PURA’s sales of EVERx CBD Sports Water are growing.  KALY is now working with PURA to formulate a 25 MG CBD formula for a new CBD infused water product.  Together, PURA and KALY have signed over a $1 million agreement to produce CBD infused water for Generex Biotechnology, Inc. (GNBT). The GNBT product is expected to be on shelves soon.  The PURA and KALY agreement with GNBT is part of a larger agreement to explore potential pharmaceutical partnerships.

To learn more about the company visit https://www.kali-extracts.com/

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.

CONTACT:
Frederick Ferri
[email protected]
(214) 210-0459